TWI778982B - 治療急性腎損傷之方法 - Google Patents
治療急性腎損傷之方法 Download PDFInfo
- Publication number
- TWI778982B TWI778982B TW106134387A TW106134387A TWI778982B TW I778982 B TWI778982 B TW I778982B TW 106134387 A TW106134387 A TW 106134387A TW 106134387 A TW106134387 A TW 106134387A TW I778982 B TWI778982 B TW I778982B
- Authority
- TW
- Taiwan
- Prior art keywords
- patient
- compound
- kidney injury
- acute kidney
- use according
- Prior art date
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title claims abstract description 67
- 208000033626 Renal failure acute Diseases 0.000 title claims abstract description 67
- 201000011040 acute kidney failure Diseases 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title abstract description 28
- 150000001875 compounds Chemical class 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 13
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 230000003589 nefrotoxic effect Effects 0.000 claims description 7
- 231100000381 nephrotoxic Toxicity 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229930183010 Amphotericin Natural products 0.000 claims description 3
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 229940009444 amphotericin Drugs 0.000 claims description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 3
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 3
- 229960003866 cefaloridine Drugs 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 229960002518 gentamicin Drugs 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- ZMJOVJSTYLQINE-UHFFFAOYSA-N Dichloroacetylene Chemical group ClC#CCl ZMJOVJSTYLQINE-UHFFFAOYSA-N 0.000 claims description 2
- 206010051920 Glomerulonephropathy Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 231100000644 Toxic injury Toxicity 0.000 claims description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 2
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000006750 hematuria Diseases 0.000 claims description 2
- 230000036543 hypotension Effects 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 claims description 2
- 230000003156 vasculitic effect Effects 0.000 claims description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 50
- 229940126062 Compound A Drugs 0.000 description 41
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 41
- 229940109239 creatinine Drugs 0.000 description 25
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 23
- 241000700159 Rattus Species 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 206010061481 Renal injury Diseases 0.000 description 11
- 230000003907 kidney function Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- -1 hydrochloric Chemical class 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000024924 glomerular filtration Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 102000013519 Lipocalin-2 Human genes 0.000 description 6
- 108010051335 Lipocalin-2 Proteins 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000037806 kidney injury Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 208000012998 acute renal failure Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 4
- 229960002725 isoflurane Drugs 0.000 description 4
- 229960003194 meglumine Drugs 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OMCDNQOMTAHLDT-UHFFFAOYSA-N CC1=CN=C(N1CC1=C(C=CC=C1)O)C=1C=NC(=CC=1)C(F)(F)F Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)O)C=1C=NC(=CC=1)C(F)(F)F OMCDNQOMTAHLDT-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 238000012311 Shapiro-Wilk normality test Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000035850 clinical syndrome Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000001422 normality test Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000010242 retro-orbital bleeding Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- PNXJWEQRIVLWBG-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1C(F)(F)F PNXJWEQRIVLWBG-UHFFFAOYSA-N 0.000 description 1
- JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WNDPXYAVRBQZAL-UHFFFAOYSA-N COC1=C(CN2C(=NC=C2C)C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C(=NC=C2C)C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 WNDPXYAVRBQZAL-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-Lysine Natural products NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- PDKXJKWLFFZPPF-UHFFFAOYSA-N [dimethylamino-(3-oxidotriazolo[4,5-b]pyridin-3-ium-1-yl)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(C(N(C)C)=[N+](C)C)N=[N+]([O-])C2=N1 PDKXJKWLFFZPPF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- OXCREIAATRYJNU-UHFFFAOYSA-N n-benzyl-2-methoxyaniline Chemical compound COC1=CC=CC=C1NCC1=CC=CC=C1 OXCREIAATRYJNU-UHFFFAOYSA-N 0.000 description 1
- SCMZYNODBBJLAB-UHFFFAOYSA-N n-prop-2-ynyl-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=C(C(=O)NCC#C)C=N1 SCMZYNODBBJLAB-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本發明係關於治療患有急性腎損傷之人類患者的方法。
Description
本發明係關於治療患有急性腎損傷之人類患者的方法。
急性腎損傷(AKI)此前稱為急性腎衰竭(ARF),其係特徵為數天內腎功能急劇惡化之一種臨床症候群。AKI主要特徵為腎小球濾過率(GFR)突然下降,導致含氮廢物(尿素、肌酐)滯留。在整個世界人口中,每年每百萬人口中發生170至200例嚴重AKI。迄今,對於已確認之AKI尚無特定治療。已發現若干種藥物預防性改善毒性及缺血性實驗AKI,如不同動物模型中較低血清肌酐含量、組織學損傷減少及腎功能更快恢復所表明。此等藥物包括抗氧化劑、鈣離子通道阻斷劑、利尿劑、影響血管的物質、生長因子、消炎劑及更多藥物。然而,已在臨床試驗中對此等藥物進行研究且顯示無益處,且尚未批准其用於臨床AKI。一旦AKI發展,則更難以進行治療。 本文所揭示之化合物為過氧化體增殖物活化受體δ (PPARδ)之例示性調節劑。PPARδ係能夠調節粒線體生物合成之核受體。已顯示調節PPARδ之活性對於治療疾病而言係有用的。
現已發現一種由以下結構式表示之化合物(R
)-3-甲基-6-(2-((5-甲基-2-(6-(三氟甲基)吡啶-3-基)-1H
-咪唑-1-基)甲基)苯氧基)己酸:(以下稱作「化合物A」) 減少急性腎病之大鼠模型的腎損傷(參見實例2)。特定言之,在對實驗室大鼠之腎誘發局部缺血再灌注損傷後靜脈內投與化合物A四個小時時,化合物A顯著降低血漿肌酐含量,改善腎功能且減少早期腎損傷生物標記NGAL。 亦已發現由以下結構式表示之化合物B:(以下稱作「化合物B」) 減少急性腎病之大鼠模型的腎損傷(參見實例3)。特定言之,在對實驗室大鼠之腎誘發局部缺血再灌注損傷後經口投與化合物B四個小時時,化合物B顯著降低血漿肌酐含量且改善腎功能。 基於此等發現,本文揭示治療急性腎損傷之方法。 本發明之一個實施例為一種治療患有急性腎損傷之人類患者的方法。該方法包含向患者靜脈內投與有效量之化合物A或其醫藥學上可接受之鹽。 本發明之另一實施例為一種治療患有急性腎損傷之人類患者的方法。該方法包含向患者投與有效量之化合物B或其醫藥學上可接受之鹽。在一個實施例中,化合物B經口投與;在另一實施例中,其靜脈內投與。 本發明之又一實施例為一種治療患有急性腎損傷之人類患者的方法。該方法包含向患者投與有效量之化合物C:(以下稱作「化合物C」); 或其醫藥學上可接受之鹽。在一個實施例中,化合物C經口投與;在另一實施例中,其靜脈內投與。 本發明之另一實施例為化合物A或其醫藥學上可接受之鹽,其用於靜脈內治療患有急性腎損傷之人類患者。 本發明之又一實施例為化合物B或其醫藥學上可接受之鹽,其用於治療患有急性腎損傷之人類患者。在一個實施例中,化合物B經口投與;在另一實施例中,化合物B靜脈內投與。 本發明之又一實施例為化合物C或其醫藥學上可接受之鹽,其用於治療患有急性腎損傷之人類患者。在一個實施例中,化合物C經口投與;在另一實施例中,化合物C靜脈內投與。 本發明之又一實施例為化合物A或其醫藥學上可接受之鹽的用途,其用於製造供靜脈內治療患有急性腎損傷之人類患者用的藥物。 本發明之又一實施例為化合物B或其醫藥學上可接受之鹽的用途,其用於製造供治療患有急性腎損傷之人類患者用的藥物。在一個實施例中,化合物B經口投與;在另一實施例中,化合物B靜脈內投與。 本發明之另一實施例為化合物C或其醫藥學上可接受之鹽的用途,其用於製造供治療患有急性腎損傷之人類患者用的藥物。在一個實施例中,化合物C經口投與;在另一實施例中,化合物B靜脈內投與。
相關申請案之交叉參考
本申請案主張2016年10月5日申請之美國臨時申請案第62/404,390號之權益。前述申請案之整個教示內容以引用的方式併入本文中。 本文提供用於治療人類患者之急性腎損傷的方法。該等方法包含向人類患者投與有效量之化合物A、化合物B或化合物C,或者化合物A、化合物B或化合物C之醫藥學上可接受之鹽。在一個實施例中,在人類患者發生急性腎損傷之後,投與化合物A、化合物B或化合物C,或者化合物A、化合物B或化合物C之醫藥學上可接受之鹽。化合物A較佳靜脈內投與。 如本文所使用,術語「急性腎損傷」或「AKI」,先前稱作「急性腎衰竭」或「ARF」,係指特徵為腎功能迅速減退之一種急性臨床症候群,其係由許多因素,諸如腎血流量降低、絲球體腎炎、使用腎毒性抗生素及抗癌劑引起。 急性腎損傷定義為腎功能突然下降,且可基於患者呈現出血清肌酐含量、腎小球濾過率或尿排出量中之一或多者的變化來診斷。舉例而言,急性腎損傷之特徵可為至少1.5倍基線之血清肌酐含量,其中基線係指不超過7天前的患者血清肌酐含量。舉例而言,患有急性腎損傷之患者可具有1.5至1.9倍基線、2.0至2.9倍基線或者3.0或大於3.0倍基線的血清肌酐含量。替代地,急性腎損傷之特徵可為至少0.3 mg/dL或至少0.4 mg/dL之血清肌酐增加。 可替代地,急性腎損傷之特徵可為小於90 mL/min/1.73 m2
之腎小球濾過率。舉例而言,患有急性腎損傷之患者可具有60-89 mL/min/1.73 m2
、30-59 mL/min/1.73 m2
、15-29 mL/min/1.73 m2
或小於15 mL/min/1.73 m2
之腎小球濾過率。 可替代地,急性腎損傷之特徵可為患者在6小時內尿輸出量小於0.5 mL/Kg、12小時內尿輸出量小於0.5 mL/Kg、12小時內尿輸出量小於0.3 mL/Kg,或者12小時或更多小時無尿。 急性腎損傷可伴隨特定腎病(例如急性間質性腎炎、急性腎小球腎病及血管炎性腎病)、非特定病況(例如局部缺血、中毒性損傷)以及腎外病變(例如腎前性氮質血症及急性腎後梗阻性腎病)而發生。超過一種此等病況可在同一患者中共存,且更重要地,流行病學證據支持以下概念:即使輕度可逆的AKI亦具有重大臨床後果,包括死亡風險增加。此外,因為不論病因主要在腎內或主要來自腎外應激,AKI之表現及臨床後果均可能極其相似(甚至無法區分),所以AKI症候群涵蓋對腎之直接損傷與功能急劇減弱兩者。 在一些實施例中,針對AKI進行治療之患者患有糖尿病、原發性腎機能不全、腎病症候群、動脈粥樣硬化病、敗血症、低血壓、低氧症、肌球蛋白尿-血尿或肝病。在其他實施例中,患者係老年人、懷孕、手術患者或已曝露於腎毒性劑。 在一特定實施例中,針對AKI進行治療之患者係手術患者。因此,在某些實施例中,化合物在手術之後投與手術患者。 在另一實施例中,針對AKI進行治療之患者已曝露於腎毒性劑。腎毒性劑係能夠造成AKI之藥物或化學物質。能夠造成急性腎損傷之藥物或化學物質包括(但不限於)順鉑(cisplatin);慶大黴素(gentamicin);頭孢噻啶(cephaloridine);環孢靈(cyclosporine);兩性黴素(amphotericin);四氯化碳;三氯乙烯;及二氯乙炔。 同樣,患有由先前三段所提及之任一病況引起之AKI的患者可用根據所揭示之方法之化合物A、化合物B或化合物C或者化合物A、化合物B或化合物C之醫藥學上可接受之鹽治療。 化合物A、化合物B及化合物C之醫藥上可接受之鹽可用於所揭示之方法。術語「醫藥學上可接受之鹽」係指在合理醫學判斷範疇內,適用於與人類及低等動物之組織接觸使用而無異常毒性、刺激及過敏反應且與合理益處/風險比相稱的醫藥鹽。醫藥學上可接受之鹽為此項技術中所熟知的。舉例而言,S. M. Berge等人在J . Pharm . Sci
., 1977,66
, 1-19中描述藥理學上可接受之鹽。鹽係由與酸(例如氫氯酸、氫溴酸、磷酸、硝酸、硫酸、乙酸、苯磺酸、苯甲酸、甲磺酸、對甲苯磺酸及葡甲胺酸)加成以及由與鹼加成形成,例如銨鹽、鹼金屬鹽(諸如鈉鹽及鉀鹽)、鹼土金屬鹽(諸如鎂鹽及鈣鹽)及有機鹼鹽(諸如葡甲胺鹽及L-離胺酸鹽)。醫藥組合物及其投與
化合物A、化合物B或化合物C,或者化合物A、化合物B或化合物C之醫藥學上可接受之鹽可與已知對AKI有益之其他藥劑組合使用。 向個體提供「有效量」而投與化合物之精確量將視投藥模式、疾病及/或病況之類型及嚴重程度,及個體之特徵,諸如總體健康狀況、年齡、性別、體重及對藥物之耐受性而定。熟習此項技術者將能夠根據此等及其他因素確定適當劑量。術語「有效量」意謂當向個體投與時,產生有利或所需結果,包括臨床結果,例如相比於對照,抑制、遏止或減輕個體所治療之病況症狀的量。舉例而言,有效量可為每日0.1 mg至約50 g。 本文所使用之術語「投與(administer)」、「投與(administering)」、「投與(administration)」及其類似術語係指可用於使組合物能夠遞送至所需生物作用部位之方法。此等方法包括(但不限於)關節內(在關節中)、靜脈內、肌肉內、腫瘤內、皮內、腹膜內、皮下、經口、局部、鞘內、吸入、經皮、經直腸及其類似方法。舉例而言,當所治療之病況為急性腎損傷時,常用經口及靜脈內投與。可與本文所述之藥劑及方法一起採用之投與技術見於例如Goodman及Gilman,The Pharmacological Basis of Therapeutics
, 當前版; Pergamon;及Remington'sPharmaceutical Sciences
(當前版), Mack Publishing Co., Easton, Pa。 用於本發明方法中之醫藥組合物包括化合物A、化合物B或化合物C或者化合物A、化合物B或化合物C之醫藥學上可接受之鹽,及典型地至少一種額外物質,諸如賦形劑、除本發明之治療劑以外的一種已知治療劑及其組合。 用於所揭示方法中之醫藥組合物經調配以與其預期投與途徑相容。在一實施例中,組合物係根據常規程序調配為適合於靜脈內、皮下、肌肉內、經口、鼻內或局部向人類投與之醫藥組合物。 藉由靜脈內調配物投與治療劑為醫藥工業中所熟知的。靜脈內調配物包含溶解於醫藥學上可接受之溶劑或溶液中之醫藥活性劑(例如化合物A、化合物B或化合物C或者化合物A、化合物B或化合物C之醫藥學上可接受之鹽),該醫藥學上可接受之溶劑或溶液為諸如無菌水、標準生理食鹽水溶液、乳酸林格氏溶液(lactated Ringer's solution)或其他諸如林格氏溶液之鹽溶液。調配物應促進該(等)活性成份之整體穩定性,此外,調配物之製備應為有成本效益的。所有此等因素最終決定靜脈內調配物之總成效及有用性。 經口調配物通常經製備為呈例如錠劑或丸劑形式之壓縮製劑。錠劑可含有例如約5%至10%之活性成分(例如化合物A、化合物B或化合物C或者化合物A、化合物B或化合物C之醫藥學上可接受之鹽)、約80%之填料、崩解劑、潤滑劑、滑動劑及黏合劑;及10%之確保錠劑在胃或腸中易於崩解、解聚及溶解的化合物。丸劑可塗佈有糖、清漆或蠟以掩蓋味道。例證 實例 1 ( R )- 3 - 甲基 - 6 -( 2 -(( 5 - 甲基 - 2 -( 6 -( 三氟甲基 ) 吡啶 - 3 - 基 )- 1H - 咪唑 - 1 - 基 ) 甲基 ) 苯氧基 ) 己酸 ( 化合物 A ) 之合成 流程: ( R )- 6 - 溴基 - 3 - 甲基己酸乙酯之合成 : 在1 L圓底燒瓶中,在室溫(RT)下,用PBr3
(101.0 g,373.56 mmol)來處理(R
)-6-羥基-3-甲基己酸乙酯(65.0 g,373.56 mmol)於二氯甲烷(650 mL)中之溶液。在室溫下攪拌反應混合物3小時。在反應完成之後(藉由TLC監測),反應混合物用水(500 mL)稀釋且用乙醚(3 × 500 mL)萃取。有機萃取物經分離且經無水Na2
SO4
乾燥。在減壓下移除溶劑,獲得標題化合物(57.12 g)。步驟 - 1 : N -( 丙 - 2 - 炔 - 1 - 基 )- 6 -( 三氟甲基 ) 菸鹼醯胺之合成: 在100 mL圓底燒瓶中,在室溫下於氮氣氛圍下,用六氟磷酸1-[雙(二甲胺基)亞甲基]-1H-1,2,3-三唑并[4,5-b]吡錠3-氧化物(7.2 g,18.84 mmol)及三乙胺(3.1 mL,23.55 mmol)處理經攪拌的6-(三氟甲基)菸鹼酸(3 g,15.70 mmol)及丙-2-炔-1-胺(1.05 g,18.84 mmol)於二甲基甲醯胺(DMF:50 mL)中之溶液。將所得反應混合物在室溫下攪拌3小時。在反應完成之後(藉由TLC監測),反應混合物用冷水稀釋且所沈澱固體經過濾,用水洗滌且在減壓下乾燥,得到標題化合物(2.6 g,72.6%)。1
H NMR (300 MHz, CDCl3
): δ 9.08 (d,J
= 2.1 Hz, 1H), 8.32 (dd,J
= 8.4, 2.4 Hz, 1H), 7.78 (d,J
= 7.8 Hz, 1H), 6.62 (brs, 1H), 4.30-4.28 (m, 2H), 2.33 (t,J
= 2.4 Hz, 1H)。 LCMS (ESI+,m/z
): 229.2 (M+H)+
。步驟 - 2 : 5 -( 1 -( 2 - 甲氧基苯甲基 )- 5 - 甲基 - 1H - 咪唑 - 2 - 基 )- 2 -( 三氟甲基 ) 吡啶之合成 : 在50 mL可重複密封之試管中,於室溫下在氮氣氛圍下,用三氟甲烷磺酸鋅(0.16 g,0.43 mmol)處理N-(丙-2-炔-1-基)-6-(三氟甲基)菸鹼醯胺(1.0 g,4.38 mmol)及2-甲氧基苯基苄基胺(1.2 g,8.77 mmol)於甲苯(10 mL)中之溶液。將反應混合物在120℃下加熱12小時。在反應完成(藉由TLC監測)之後,反應混合物用水稀釋且用EtOAc (3 × 20 mL)萃取。有機萃取物用飽和NaHCO3
、鹽水洗滌且經無水Na2
SO4
乾燥。在減壓下濃縮溶液且藉由矽膠管柱層析法(溶離,含25% EtOAc之己烷)純化所獲得之殘餘物,得到標題化合物(0.8 g,52.6%)。1
H NMR (400 MHz, CDCl3
): δ 8.79 (s, 1H), 8.07 (d,J
= 8.1 Hz, 1H), 7.68 (d,J
= 8.1 Hz, 1H), 7.31 (t,J
= 8.4 Hz, 1H), 7.09 (s, 1H), 6.94-6.87 (m, 2H), 6.56 (d,J
= 7.5 Hz, 1H), 5.16 (s, 2H), 3.87 (s, 3H)。LCMS (ESI+,m/z
): 348.3 (M+H)+
。步驟 - 3 : 2 -(( 5 - 甲基 - 2 -( 6 -( 三氟甲基 ) 吡啶 - 3 - 基 )- 1H - 咪唑 - 1 - 基 ) 甲基 ) 苯 酚之合成 : 在100 mL圓底燒瓶中,在0℃下用BBr3
(0.8 mL,2.31 mmol)逐滴處理5-(1-(2-甲氧基苯甲基)-5-甲基-1H
-咪唑-2-基)-2-(三氟甲基)吡啶(0.8 g,2.31 mmol)於二氯甲烷(300 mL)中之溶液。在室溫下攪拌反應混合物2小時。在反應完成(藉由TLC監測)之後,反應混合物用NaHCO3
水溶液鹼化(約pH 9)且用乙酸乙酯(EtOAc)萃取。有機萃取物經無水Na2
SO4
乾燥且在減壓下濃縮,得到標題化合物(0.5 g,65.1%)。1
H NMR (400 MHz, DMSO-d6
): δ 9.92 (s, 1H), 8.83 (s, 1H), 8.12 (d,J
= 8.1 Hz, 1H), 7.94 (d,J
= 8.1 Hz, 1H), 7.12 (d,J
= 6.9 Hz, 1H), 7.02 (s, 1H), 6.87 (d,J
= 7.8 Hz 1H), 6.73 (t,J
= 7.2 Hz, 1H), 6.37 (d,J
= 7.2 Hz, 1H), 5.20 (s, 2H), 2.15 (s, 3H)。 LCMS (ESI+,m/z
): 334.3 (M+H)+
。步驟 - 4 : ( R )- 3 - 甲基 - 6 -( 2 -(( 5 - 甲基 - 2 -( 6 -( 三氟甲基 ) 吡啶 - 3 - 基 )- 1H - 咪唑 - 1 - 基 ) 甲基 ) 苯氧基 ) 己酸乙酯之合成 : 在50 mL圓底燒瓶中,在室溫下於氮氣氛圍下,用K2
CO3
(0.41 g,3.00 mmol)及(R
)-6-溴基-3-甲基己酸乙酯(0.710 g,3.00 mmol)處理經攪拌的2-((5-甲基-2-(6-(三氟甲基)吡啶-3-基)-1H
-咪唑-1-基)甲基)苯酚(0.5 g,1.50 mmol)於DMF (10 mL)中之溶液。在60℃下將所得反應混合物加熱12小時。在反應完成(藉由TLC監測)之後,反應混合物用冰冷水淬滅且用乙酸乙酯萃取(75 mL×3)。經合併之有機萃取物用鹽水洗滌,經無水Na2
SO4
乾燥且在減壓下濃縮。藉由矽膠管柱層析法(梯度溶離,含15%至30% EtOAc之己烷)純化所獲得之殘餘物,得到標題化合物(0.45 g,61.3%)。 產量: 0.45 g (61.3%)。 LCMS (ESI+,m/z
): 491.0 (M+H)+
。步驟 - 5 : ( R )- 3 - 甲基 - 6 -( 2 -(( 5 - 甲基 - 2 -( 6 -( 三氟甲基 ) 吡啶 - 3 - 基 )- 1H - 咪唑 - 1 - 基 ) 甲基 ) 苯氧基 ) 己酸 ( 化合物 A ) 之合成 : 在250 mL圓底燒瓶中,在室溫下,用單水合氫氧化鋰(16.0 g,74.33 mmol)處理經攪拌的(R
)-3-甲基-6-(2-((5-甲基-2-(6-(三氟甲基)吡啶-3-基)-1H
-咪唑-1-基)甲基)苯氧基)己酸乙酯(0.45 g,0.92 mmol)於四氫呋喃(THF:5 mL)、乙醇(2.5 mL)及水(2.5 mL)中之溶液。在室溫下攪拌反應混合物12小時。在反應完成(藉由TLC監測)之後,反應混合物在減壓濃縮。所獲得之殘餘物用EtOAc洗滌,用冷水稀釋且用1N HCl酸化(約pH 5)。過濾固體且在減壓下乾燥,得到標題化合物(0.166 g,39.2%)。1
H NMR (400 MHz, DMSO-d6
): δ 11.96 (brs, 1H), 8.79 (s, 1H), 8.05 (d,J
= 8.0 Hz, 1H), 7.90 (d,J
= 8.0 Hz, 1H), 7.24 (t,J
= 7.6 Hz, 1H), 7.02 (d,J
= 8.4 Hz, 1H), 7.00 (s, 1H), 6.84 (t,J
= 7.6 Hz, 1H), 6.43 (d,J
= 7.2 Hz, 1H), 5.21 (s, 2H), 3.98 (t,J
= 6.0 Hz, 2H), 2.19-2.14 (m, 1H), 2.13 (s, 3H), 2.03-1.94 (m, 1H), 1.85-1.80 (m, 1H), 1.68-1.66 (m, 2H), 1.38-1.36 (m, 1H), 1.28-1.18 (m, 1H), 0.85 (d,J
= 6.4 Hz, 3H)。19
F NMR (400 MHz, DMSO-d6
): δ -66.46 LCMS (ESI+,m/z
): 462.3 (M+H)+
。 HPLC: 95.11 % (210 nm)。化合物 A 之葡甲胺鹽的製備
使用兩種獨立的方法來產生化合物A之葡甲胺鹽。方法 1
在4 mL玻璃小瓶中將化合物A (102.7 mg)與葡甲胺(43.7 mg)及2 mL之2-丙醇組合。用蓋密封小瓶且使內含物25℃下經受音波處理20分鐘,隨後在50℃下攪拌60分鐘。接著將小瓶移動至新的攪拌板且在25℃下攪拌小瓶中之漿液。方法 2
在4 mL玻璃小瓶中將化合物A (102.2 mg)與葡甲胺(43.2 mg)及2 mL之乙腈組合。用蓋密封小瓶且使內含物在25℃下經受音波處理20分鐘,隨後在50℃下攪拌60分鐘。接著將小瓶移動至新的攪拌板且在25℃下攪拌小瓶中之漿液。 對於方法1及方法2兩者,在25℃下攪拌2天之後,將兩個樣本離心,棄去上清液且將固體風乾。化合物 A 之葡甲胺鹽之水合物的製備
在500 mL圓底燒瓶中,在0℃下用葡甲胺(8.45 g,43.33 mmol)處理經攪拌的化合物A (20 g,43.33 mmol)於THF (100 mL)及水(100 mL)中之溶液。將所得反應混合物在室溫下攪拌6小時。在減壓下濃縮反應混合物且在減壓下乾燥所獲得之固體(3小時),得到呈白色固體狀之標題化合物(28.5 g,98.95%)。1
H NMR (400 MHz, CD3
OD): δ 8.75 (s, 1H), 8.02 (d,J
= 8.4 Hz, 1H), 7.82 (d,J
= 8.0 Hz 1H), 7.26 (t,J
= 8.4 Hz, 1H), 7.03 (s,1H), 6.99 (d,J
= 8 Hz, 1H), 6.85 (t,J
= 7.6 Hz, 1H), 6.50 (d,J
= 7.6 Hz, 1H), 5.25 (s, 2H), 4.09-3.99 (m, 3H), 3.97-3.77 (m, 2H), 3.74-3.61 (m, 3H), 3.29-3.06 (m, 2H), 2.64 (s, 3H), 2.22 (s, 3H), 2.18-2.14 (m, 1H), 1.99 - 1.94 (m, 2H), 1.83 - 1.75 (m, 2H), 1.51 - 1.38 (m, 1H), 1.32-1.22 (m, 1H), 0.86 (d,J
= 6.0 Hz, 3H)。19
F NMR (400 MHz, CD3
OD): δ -69.39 元素分析: C31
H43
F3
N4
O8
.H2
O計算值: C, 55.18; H, 6.72; N, 8.30。實驗值: C, 54.95; H, 6.89; N, 8.07 水分含量(卡-費法(Karl Fischer)): 2.33%實例 2 當在急性腎損傷之動物模型中靜脈內投與時 , 化合物 A 減少 局部缺血再灌注損傷 動物、手術及給藥 :
在此等實驗中使用大約280至300 g史泊格-多利(Sprague-Dawley)雄性大鼠,標準饋料及水隨意取用。將大鼠(n=8/組)用異氟醚麻醉且將其腹側置放於溫控加熱之手術台上。在背側表面上切開皮膚,經由側切口暴露兩個腎。將血管夾施加至兩個腎蒂且閉塞持續45分鐘。45分鐘之後,移除夾,針對成功再灌注對腎進行監測且隨後縫合手術部位。除不施加閉塞夾具以外,使假處理組(n=4隻大鼠)經受類似手術程序。化合物A經調配為每天新製的化合物A (1.5莫耳當量化合物A)之葡甲胺鹽之水合物於5%右旋糖中的澄清溶液。在動物自手術醒來4小時後,經由尾靜脈以3 mg/kg、1 mg/kg或0.3 mg/kg靜脈內給與化合物A且類似地向假手術及IRI對照動物給與媒劑。血液採集 :
再灌注二十四(24)小時之後,在輕度異氟醚麻醉下藉由自所有組進行後眼眶取血,將血液採集於K2 EDTA管中。在4℃下,藉由以3000 rpm離心10分鐘來分離血漿。尿液採集 :
在手術恢復之後立即將所有研究動物組置放於代謝籠中且採集尿液24或48小時。仔細量測尿液體積,且隨後在4℃下以3000 rpm離心10分鐘來移除沈積物。 血漿及尿肌酐使用完全自動之臨床生物化學分析器(Siemens Dimension ® Xpand ® Plus Integrated Chemistry System)來分析。Urinary NGAL使用BioPorto ELISA套組來分析。肌酐清除率計算如下: 資料分析及統計分析 :
GraphPad Prism軟體第6.05版用於繪圖及統計測試。經由D'Agostino Pearson綜合常態檢驗及Shapiro-Wilk常態檢驗來測試所有組中肌酐之常態分佈。統計顯著性(p<0.05)藉由一般單因子變異數分析(One-way ANOVA),接著使用IRI處理組作為對照組進行鄧尼特多重比較(Dunnett's multiple comparison)來確定。對比IR-媒劑,**p<0.01,***p<0.001及****p<0.0001。結果:
資料顯示於圖1中。在局部缺血4小時後靜脈內給藥之化合物A減少腎損傷。化合物A在以0.3 mg/kg、1 mg/kg或3 mg/kg給藥時,顯著降低血漿肌酐,改善腎功能且減少早期腎損傷生物標記NGAL。實例 3 當在急性腎損傷之動物模型中經口投與時 , 化合物 B 減少 局部缺血再灌注損傷 動物、手術及給藥 :
在此等實驗中使用大約280至300 g史泊格-多利雄性大鼠,標準饋料及水隨意取用。將大鼠(n=8/組)用異氟醚麻醉且將其腹側置放於溫控加熱之手術台上。在背側表面上切開皮膚,經由側切口暴露兩個腎。將血管夾施加至兩個腎蒂且閉塞持續45分鐘。45分鐘之後,移除夾,針對成功再灌注對腎進行監測且縫合手術部位。除不施加閉塞夾具以外,使假處理組(n=4隻大鼠)經受類似手術程序。將化合物B調配為每天新製的於含0.25%羧甲基纖維素鈉、0.25% Tween-80之淨化水中的懸浮液。在動物自手術醒來4小時後,以30 mg/kg經口給與化合物B且類似地向假手術及IRI對照動物給與媒劑。血液採集 :
再灌注二十四(24)小時之後,在輕度異氟醚麻醉下藉由自所有組進行後眼眶取血,將血液採集於K2 EDTA管中。在4℃下,藉由以3000 rpm離心10分鐘來分離血漿。尿液採集 :
在手術恢復之後立即將所有研究動物組置放於代謝籠中且採集尿液24小時。仔細量測尿液體積,且隨後在4℃下以3000 rpm離心10分鐘來移除沈積物。 血漿及尿肌酐使用完全自動之臨床生物化學分析器(Siemens Dimension ® Xpand ® Plus Integrated Chemistry System)來分析。肌酐清除率計算如下: 資料分析及統計分析 :
GraphPad Prism軟體第6.05版用於繪圖及統計測試。經由D'Agostino Pearson綜合常態檢驗及Shapiro-Wilk常態檢驗來測試所有組中之資料常態分佈。常態分佈之資料經受不成對雙尾t檢驗。非常態分佈之資料經受Mann-Whitney檢驗(非參數)。藉由IRI媒劑組相比於化合物處理組,p<0.05來確定統計顯著性。與IR-媒劑對比,**p<0.01及***p<0.001。結果:
在局部缺血4小時後給與之化合物B減少腎損傷。化合物B (圖2)在經口投與時降低血漿肌酐且改善腎功能。條形圖a顯示在大鼠腎損傷24小時後以mg/dL為單位之血漿肌酐含量,當經口投與時,血漿肌酐降低。直條自左至右表示給與媒劑之假手術大鼠、給與媒劑之急性腎損傷大鼠及給與30 mpk之化合物B之急性腎損傷大鼠的血漿肌酐含量(圖2a)。類似地,條形圖b顯示肌酐清除量,一種腎功能之評估,或GFR(腎小球濾過率)(圖2b)。
圖 1
a、b及c為顯示急性腎損傷之大鼠模型中靜脈內投與化合物A之治療效果的條形圖。條形圖1a顯示大鼠腎損傷後24小時以mg/dL為單位的血漿肌酐含量。直條自左至右表示無腎損傷大鼠靜脈內投與媒劑及腎損傷大鼠靜脈內投與媒劑;0.3 mpk之化合物A;1 mpk之化合物A;及3.0 mpk之化合物A的血漿肌酐含量。類似地,條形圖1b顯示腎損傷後24小時的肌酐清除量,一種腎功能之評估,或GFR (腎小球濾過率),及條形圖1c顯示腎損傷後48小時的尿中NGAL (嗜中性白血球明膠酶相關脂質運載蛋白(Lipocalin))含量。NGAL係常用於臨床中之早期腎損傷生物標記。圖 2
a及2
b為顯示急性腎損傷之大鼠模型中化合物B之治療效果的條形圖。條形圖2a顯示大鼠腎損傷後24小時以mg/dL為單位的血漿肌酐含量。直條自左至右表示給藥30 mpk媒劑之假手術大鼠、給藥30 mpk媒劑之急性腎損傷大鼠及給藥30 mpk之化合物B的急性腎損傷大鼠中的血漿肌酐含量。類似地,條形圖2b顯示肌酐清除量,一種腎功能之評估,或GFR(腎小球濾過率)。
Claims (17)
- 如請求項1之用途,其中將有效量之該化合物之葡甲胺鹽靜脈內投與該患者。
- 如請求項1之用途,其中該患者係手術患者,且在手術後將該化合物或其醫藥學上可接受之鹽投與至該患者。
- 如請求項2之用途,其中該患者係手術患者,且在手術後將該化合物或其醫藥學上可接受之鹽投與至該患者。
- 如請求項1之用途,其中該化合物或其醫藥學上可接受之鹽以每日0.1mg至約50g的有效量投與。
- 如請求項2之用途,其中該化合物或其醫藥學上可接受之鹽以每日0.1mg至約50g的有效量投與。
- 如請求項1至6中任一項之用途,其中該患者係治療由急性間質性腎炎引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中該患者係治療由腎小球腎病引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中該患者係治療由急性血管炎性腎病引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中該患者係治療由局部缺血引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中該患者係治療由中毒性損傷引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中該患者係治療由腎前性氮質血症(prerenal azotemia)引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中該患者係治療由急性腎後破壞性腎病引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中該患者係治療由糖尿病、原發性腎機能不全(underlying renal insufficiency)、腎病症候群、動脈粥樣硬 化病、敗血症、低血壓、低氧症、肌球蛋白尿-血尿或肝病引起之急性腎損傷。
- 如請求項1至6中任一項之用途,其中待治療急性腎損傷之患者係老年人、懷孕者、手術患者,或已曝露於腎毒性劑。
- 如請求項1至6中任一項之用途,其中該患者已曝露於腎毒性劑且該腎毒性劑係能夠造成急性腎損傷之藥物或化學物質。
- 如請求項16之用途,其中該藥物或化學物質為選自由順鉑、慶大黴素(gentamicin)、頭孢噻啶(cephaloridine)、環孢靈(cyclosporine)、兩性黴素(amphotericin)、四氯化碳、三氯乙烯及二氯乙炔組成之群之化合物中的一或多者。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662404390P | 2016-10-05 | 2016-10-05 | |
US62/404,390 | 2016-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201815391A TW201815391A (zh) | 2018-05-01 |
TWI778982B true TWI778982B (zh) | 2022-10-01 |
Family
ID=60153507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106134387A TWI778982B (zh) | 2016-10-05 | 2017-10-05 | 治療急性腎損傷之方法 |
Country Status (32)
Country | Link |
---|---|
US (1) | US20210283116A1 (zh) |
EP (1) | EP3522880B1 (zh) |
JP (1) | JP7065839B2 (zh) |
KR (1) | KR20190062502A (zh) |
CN (1) | CN109789117B (zh) |
AU (1) | AU2017340760B2 (zh) |
BR (1) | BR112019005539A2 (zh) |
CA (1) | CA3036723A1 (zh) |
CO (1) | CO2019004561A2 (zh) |
CY (1) | CY1124759T1 (zh) |
DK (1) | DK3522880T3 (zh) |
ES (1) | ES2859487T3 (zh) |
HR (1) | HRP20210294T1 (zh) |
HU (1) | HUE053557T2 (zh) |
IL (1) | IL265749A (zh) |
JO (1) | JOP20190056B1 (zh) |
LT (1) | LT3522880T (zh) |
MA (1) | MA46459B1 (zh) |
MD (1) | MD3522880T2 (zh) |
MX (1) | MX2019003949A (zh) |
MY (1) | MY192385A (zh) |
PH (1) | PH12019500725A1 (zh) |
PL (1) | PL3522880T3 (zh) |
PT (1) | PT3522880T (zh) |
RS (1) | RS61573B1 (zh) |
RU (1) | RU2753607C2 (zh) |
SG (1) | SG11201901925RA (zh) |
SI (1) | SI3522880T1 (zh) |
TW (1) | TWI778982B (zh) |
UA (1) | UA124019C2 (zh) |
WO (1) | WO2018067857A1 (zh) |
ZA (1) | ZA201901743B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113004205B (zh) | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
ES2861503T3 (es) * | 2016-04-13 | 2021-10-06 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
JP7017563B2 (ja) | 2016-10-05 | 2022-02-08 | ミトブリッジ,インコーポレーテッド | Pparアゴニスト化合物の結晶性および塩形態 |
CA3147699A1 (en) * | 2019-07-19 | 2021-01-28 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries |
US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201722919A (zh) * | 2015-10-07 | 2017-07-01 | 米突倍基公司 | 過氧化物酶體增生劑活化之受體(ppar)促效劑其化合物其醫藥組合物及其使用方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2555031T3 (es) | 2003-09-19 | 2015-12-28 | Janssen Pharmaceutica N.V. | Ácidos y análogos 4-((fenoxialquilo)tio)-fenoxiacéticos |
RU2006145872A (ru) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | Замещенные триазолы в качестве модуляторов ppar и способы их получения |
RU2320341C1 (ru) * | 2006-06-13 | 2008-03-27 | Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук | Средство для лечения острой обструкции верхних мочевыводящих путей |
KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス,インコーポレイティド | 小型高密度ldl粒子を減少させる方法 |
US7928067B2 (en) * | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
JP2016512201A (ja) | 2013-03-08 | 2016-04-25 | アッヴィ・インコーポレイテッド | 急性腎障害の治療方法 |
WO2014165827A1 (en) * | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
EP2862574A1 (en) | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
JP2016540759A (ja) * | 2013-12-03 | 2016-12-28 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
WO2016057656A1 (en) * | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases |
US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
-
2017
- 2017-10-05 MA MA46459A patent/MA46459B1/fr unknown
- 2017-10-05 BR BR112019005539A patent/BR112019005539A2/pt active Search and Examination
- 2017-10-05 CA CA3036723A patent/CA3036723A1/en active Pending
- 2017-10-05 SI SI201730653T patent/SI3522880T1/sl unknown
- 2017-10-05 LT LTEP17787773.5T patent/LT3522880T/lt unknown
- 2017-10-05 RS RS20210203A patent/RS61573B1/sr unknown
- 2017-10-05 JO JOP/2019/0056A patent/JOP20190056B1/ar active
- 2017-10-05 DK DK17787773.5T patent/DK3522880T3/da active
- 2017-10-05 AU AU2017340760A patent/AU2017340760B2/en active Active
- 2017-10-05 KR KR1020197012516A patent/KR20190062502A/ko not_active Application Discontinuation
- 2017-10-05 SG SG11201901925RA patent/SG11201901925RA/en unknown
- 2017-10-05 MX MX2019003949A patent/MX2019003949A/es unknown
- 2017-10-05 PL PL17787773T patent/PL3522880T3/pl unknown
- 2017-10-05 PT PT177877735T patent/PT3522880T/pt unknown
- 2017-10-05 JP JP2019518278A patent/JP7065839B2/ja active Active
- 2017-10-05 HU HUE17787773A patent/HUE053557T2/hu unknown
- 2017-10-05 WO PCT/US2017/055400 patent/WO2018067857A1/en unknown
- 2017-10-05 UA UAA201904011A patent/UA124019C2/uk unknown
- 2017-10-05 TW TW106134387A patent/TWI778982B/zh active
- 2017-10-05 ES ES17787773T patent/ES2859487T3/es active Active
- 2017-10-05 MY MYPI2019001558A patent/MY192385A/en unknown
- 2017-10-05 RU RU2019111421A patent/RU2753607C2/ru active
- 2017-10-05 MD MDE20190903T patent/MD3522880T2/ro unknown
- 2017-10-05 CN CN201780062021.8A patent/CN109789117B/zh active Active
- 2017-10-05 US US16/334,384 patent/US20210283116A1/en not_active Abandoned
- 2017-10-05 EP EP17787773.5A patent/EP3522880B1/en active Active
-
2019
- 2019-03-20 ZA ZA2019/01743A patent/ZA201901743B/en unknown
- 2019-04-01 IL IL265749A patent/IL265749A/en unknown
- 2019-04-03 PH PH12019500725A patent/PH12019500725A1/en unknown
- 2019-05-03 CO CONC2019/0004561A patent/CO2019004561A2/es unknown
-
2021
- 2021-02-22 HR HRP20210294TT patent/HRP20210294T1/hr unknown
- 2021-02-23 CY CY20211100148T patent/CY1124759T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201722919A (zh) * | 2015-10-07 | 2017-07-01 | 米突倍基公司 | 過氧化物酶體增生劑活化之受體(ppar)促效劑其化合物其醫藥組合物及其使用方法 |
Non-Patent Citations (3)
Title |
---|
期刊 Emmanuel Letavernier, et al. "Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure." J Am Soc Nephrol. 16(8) 2005 Aug 2395-2402 * |
期刊 Eun Young Lee, et al. "Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes." Nephrol Dial Transplant. 27(11) 2012 Nov 4069-4079; * |
期刊 Larisa V Fedorova, et al. " Peroxisome proliferator-activated receptor δ agonist, HPP593, prevents renal necrosis under chronic ischemia." PLoS One. 8(5) 2013 May 15 e64436; * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI778982B (zh) | 治療急性腎損傷之方法 | |
BRPI0709644A2 (pt) | sal, processo para a preparação de um sal, solução aquosa, uso de um sal, composição famacêutica, processo para a preparação de uma composição farmacêutica, e, produto | |
JP2022537570A (ja) | がんを処置する方法 | |
TWI415613B (zh) | Anti-cancer agent resistance to overcome the agent | |
WO2009051909A1 (en) | Compounds having activity in correcting mutant-cftr cellular processing and uses thereof | |
JP2018526417A (ja) | 高尿酸血症又は痛風の治療又は予防用化合物 | |
CN105518000A (zh) | 用于治疗囊性纤维化的化合物 | |
RU2468015C2 (ru) | Полиморфные формы деферасирокса (icl670a) | |
US20220289749A1 (en) | Targeted therapeutics | |
BR112019018615B1 (pt) | Composto antimicrobiano e sua composiqao farmaceutica | |
EP3730509A1 (en) | Compound for treating metabolic diseases and preparation method and use thereof | |
US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
JP2019518060A (ja) | ハロゲン化合物およびその軸性キラリティ異性体 | |
JP2018515454A (ja) | 尿酸輸送体阻害剤のナトリウム塩およびその結晶形 | |
JP2021503442A (ja) | 中枢および末梢神経系障害の治療のためのキナーゼ阻害剤 | |
JP2024500874A (ja) | がんを処置する方法 | |
TWI741240B (zh) | 含有1,4-苯并硫氮呯-1-氧化物衍生物之光學異構物之腎功能障礙的改善藥 | |
JP4235000B2 (ja) | 糸球体疾患治療剤 | |
JP5102849B2 (ja) | N−ヒドロキシ−4−{5−[4−(5−イソプロピル−2−メチル−1,3−チアゾール−4−イル)フェノキシ]ペントキシ}ベンズアミジン2エタンスルホン酸塩、その製造方法およびそれを含む薬学組成物 | |
WO2006082820A1 (ja) | 性器ヘルペス治療剤 | |
JP2018535243A (ja) | ダニリキシンの静脈内注射用製剤 | |
WO2024023696A1 (en) | Dosing regimen for a nlrp3 inhibitor | |
WO2023225300A2 (en) | Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto | |
CN116648445A (zh) | 治疗或预防慢性肾脏病的方法 | |
TW201900652A (zh) | 製備雜環衍生化合物之方法、包括該化合物之組成物及該化合物之水合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent |